Abbott’s HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
May 10, 2011
Abbott Park, Illinois (NYSE: ABT) — Abbott’s HUMIRA® (adalimumab) met its primary endpoint of clinical remission in a Phase III study of adult patients with moderate to severe ulcerative colitis. Results were presented at the Digestive Disease Week (DDW) scientific conference in Chicago.
Ulcerative colitis (UC) is a chronic autoimmune disease that causes inflammation and ulceration in the lining of the colon or large intestine. It is estimated that approximately 700,000 people in the United States have UC. Symptoms include abdominal cramping, rectal bleeding, increased bowel movements and diarrhea.
Reads Full Abbott’s HUMIRA® (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study Press Release